首页 | 本学科首页   官方微博 | 高级检索  
     


Cervical cancer prevention and control in women living with human immunodeficiency virus
Authors:Philip E. Castle PhD  MPH  Mark H. Einstein MD  MS  Vikrant V. Sahasrabuddhe MBBS  MPH   DrPH
Affiliation:1. Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, Maryland;2. Department of Obstetrics, Gynecology, and Reproductive Health, Rutgers New Jersey Medical School, Newark, New Jersey
Abstract:Despite being highly preventable, cervical cancer is the fourth most common cancer and cause of cancer death in women globally. In low-income countries, cervical cancer is often the leading cause of cancer-related morbidity and mortality. Women living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome are at a particularly high risk of cervical cancer because of an impaired immune response to human papillomavirus, the obligate cause of virtually all cervical cancers. Globally, approximately 1 in 20 cervical cancers is attributable to HIV; in sub-Saharan Africa, approximately 1 in 5 cervical cancers is due to HIV. Here, the authors provide a critical appraisal of the evidence to date on the impact of HIV disease on cervical cancer risk, describe key methodologic issues, and frame the key outstanding research questions, especially as they apply to ongoing global efforts for prevention and control of cervical cancer. Expanded efforts to integrate HIV care with cervical cancer prevention and control, and vice versa, could assist the global effort to eliminate cervical cancer as a public health problem.
Keywords:Africa  cervical cancer  cytology  human immunodeficiency virus (HIV)  human papillomavirus (HPV)  low-income and middle-income countries (LMICs)  prevention  screening  vaccination  visual inspection after acetic acid (VIA)
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号